Intech Investment Management Reduces $37M in Bristol-Myers Squibb Company ($BMY)

Intech Investment Management has significantly reduced its position in Bristol-Myers Squibb Company (NYSE: BMY). According to its latest 13F filing with the SEC, Intech slashed its holdings by 58.76% during the reporting period, selling 643,255 shares. This reduction leaves the fund with 451,521 shares valued at approximately $25.8 million.

What Changed in Intech Investment Management's Bristol-Myers Squibb Position

Intech Investment Management's recent filing shows a substantial cut in its Bristol-Myers Squibb stake. Previously holding 1,094,776 shares, the fund now has 451,521 shares, following a reduction of 643,255 shares. This move reflects a 58.76% decrease in its position.

Other Institutional Activity in Bristol-Myers Squibb

Other institutional investors have also adjusted their positions in Bristol-Myers Squibb. BlackRock, Inc. trimmed its holdings by 5,142,518 shares, ending with 171,682,888 shares worth about $10.41 billion. Meanwhile, Vanguard Capital Management LLC substantially increased its stake by 132,320,240 shares to hold the same amount, valued at approximately $8.03 billion. State Street Corp added 584,476 shares, bringing its total to 98,564,914 shares valued at $5.98 billion. JPMorgan Chase & Co saw a notable increase of 17,107,541 shares, now holding 92,475,194 shares worth $5.52 billion.

Bristol-Myers Squibb Stock Snapshot

Shares of Bristol-Myers Squibb (NYSE: BMY) traded around $57.13. The company boasts a market cap of $116.66 billion, with a P/E ratio of 16.00 and a forward P/E of 9.27. Its beta is 0.238, indicating lower volatility compared to the broader market. The stock's 52-week range is between $42.52 and $62.89, with a 50-day moving average of $57.65 and a 200-day moving average of $53.42.

Recent Earnings

Bristol-Myers Squibb reported revenue of $48.48 billion, reflecting a growth rate of 2.6%. The company's net margin stands at 15.01%, with a return on equity of 38.73%. Earnings per share were $3.57. The next earnings report is expected on July 30, 2026.

Dividend

Bristol-Myers Squibb offers an annual dividend rate of $2.52, yielding 4.41%. The dividend payout ratio is 70.03%, providing a steady income stream for investors.

Insider Buying and Selling at Bristol-Myers Squibb Company

Recent insider activity at Bristol-Myers Squibb includes sales by Wendy Short Bartie, EVP of Corporate Affairs, who sold 8,040 shares on June 3, 2026, and 3,876 shares at an average price of $54.72 the same day. Meanwhile, Adam Lenkowsky, EVP and Chief Commercial Officer, sold 203 shares on May 1, 2026.

Analysts Set New Price Targets

On April 9, 2026, B of A Securities maintained its "buy" rating with a $67 price target. Cantor Fitzgerald kept a "hold" rating with a $54 target on April 8, while HSBC maintained a "hold" rating with a $60 target on March 17. The consensus among analysts is "hold," with an average target price of $63.08 based on 25 analyst opinions.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey. It focuses on discovering, developing, and selling medicines for serious diseases in areas like oncology, hematology, and cardiovascular health. The company, led by CEO Dr. Christopher S. Boerner, employs approximately 32,500 people worldwide.

Bottom Line

Intech Investment Management's significant reduction in its Bristol-Myers Squibb stake highlights ongoing shifts in institutional holdings. While the stock remains a staple in healthcare portfolios, investors are closely watching for updates. It's important to remember that 13F filings are backward-looking and may not reflect current positions.